NASDAQ:IFRX - Inflarx Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$32.40 -1.20 (-3.57 %)
(As of 07/22/2018 02:51 AM ET)
Previous Close$32.40
Today's Range$31.50 - $36.00
52-Week Range$14.47 - $42.83
Volume19,087 shs
Average Volume21,009 shs
Market Capitalization$786.58 million
P/E Ratio-11.02
Dividend YieldN/A
BetaN/A
Inflarx logoInflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive IFRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IFRX
CUSIPN/A
Phone49-36-4150-8180

Debt

Debt-to-Equity RatioN/A
Current Ratio27.71
Quick Ratio27.71

Price-To-Earnings

Trailing P/E Ratio-11.02
Forward P/E Ratio-19.52
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.77 per share
Price / Book5.62

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees21
Outstanding Shares23,410,000
Market Cap$786.58

Inflarx (NASDAQ:IFRX) Frequently Asked Questions

What is Inflarx's stock symbol?

Inflarx trades on the NASDAQ under the ticker symbol "IFRX."

How were Inflarx's earnings last quarter?

Inflarx NV (NASDAQ:IFRX) announced its quarterly earnings results on Thursday, May, 17th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.06. View Inflarx's Earnings History.

When is Inflarx's next earnings date?

Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, August, 16th 2018. View Earnings Estimates for Inflarx.

What price target have analysts set for IFRX?

6 brokerages have issued 12 month price objectives for Inflarx's stock. Their predictions range from $30.00 to $55.00. On average, they anticipate Inflarx's share price to reach $42.6667 in the next twelve months. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Ratings for Inflarx.

What is the consensus analysts' recommendation for Inflarx?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Inflarx's key competitors?

Who are Inflarx's key executives?

Inflarx's management team includes the folowing people:
  • Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director
  • Prof. Renfeng Guo M.D., Co-Founder, Chief Scientific Officer & Exec. Director (Age 48)
  • Mr. Arnd Christ MBA, Chief Financial Officer (Age 52)
  • Dr. Maria Habel PH.D., Head of Preclinical R&D (Age 36)
  • Dr. Othmar Zenker M.D., Chief Medical Officer (Age 56)

When did Inflarx IPO?

(IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Has Inflarx been receiving favorable news coverage?

News articles about IFRX stock have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inflarx earned a media sentiment score of 0.20 on Accern's scale. They also assigned news stories about the company an impact score of 47.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Inflarx?

Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inflarx's stock price today?

One share of IFRX stock can currently be purchased for approximately $32.40.

How big of a company is Inflarx?

Inflarx has a market capitalization of $786.58 million. The company earns $-27,390,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Inflarx employs 21 workers across the globe.

How can I contact Inflarx?

Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180.


MarketBeat Community Rating for Inflarx (NASDAQ IFRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  144
MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.